Gestonorone acetate, or gestronol acetate, also known as norhydroxyprogesterone acetate, is a progestin of the 19-norprogesterone and 17ñ-hydroxyprogesterone groups which was developed in the early 1960s but was never marketed. It is the C17ñ acetate ester of gestronol (17ñ-hydroxy-19-norprogesterone).
Gestonorone acetate has been found to consistently inhibit ovulation at an oral dosage of 10 mg/day in combination with 50 üg/day oral ethinylestradiol. Weak or no endometrial effects were observed at an oral dosage of 100 mg/day, basal vacuoles appeared at 130 to 140 mg/day, and full endometrial secretory transformation occurred at 220 mg/day.